CN110840899A - 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放 - Google Patents

用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放 Download PDF

Info

Publication number
CN110840899A
CN110840899A CN201910977574.7A CN201910977574A CN110840899A CN 110840899 A CN110840899 A CN 110840899A CN 201910977574 A CN201910977574 A CN 201910977574A CN 110840899 A CN110840899 A CN 110840899A
Authority
CN
China
Prior art keywords
fat
compound
sustained release
implant
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910977574.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·M·惠特卡普
D·F·伍德沃
P·M·休斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN110840899A publication Critical patent/CN110840899A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
CN201910977574.7A 2013-04-12 2014-04-09 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放 Pending CN110840899A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
US61/811,682 2013-04-12
CN201480020790.8A CN105101962A (zh) 2013-04-12 2014-04-09 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480020790.8A Division CN105101962A (zh) 2013-04-12 2014-04-09 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放

Publications (1)

Publication Number Publication Date
CN110840899A true CN110840899A (zh) 2020-02-28

Family

ID=51686960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910977574.7A Pending CN110840899A (zh) 2013-04-12 2014-04-09 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放
CN201480020790.8A Pending CN105101962A (zh) 2013-04-12 2014-04-09 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480020790.8A Pending CN105101962A (zh) 2013-04-12 2014-04-09 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放

Country Status (18)

Country Link
US (2) US20140308354A1 (cg-RX-API-DMAC7.html)
EP (2) EP2983663B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016520561A (cg-RX-API-DMAC7.html)
KR (1) KR20150141972A (cg-RX-API-DMAC7.html)
CN (2) CN110840899A (cg-RX-API-DMAC7.html)
AU (2) AU2014250937A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015025915A8 (cg-RX-API-DMAC7.html)
CA (1) CA2908731A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015003023A1 (cg-RX-API-DMAC7.html)
DK (1) DK2983663T3 (cg-RX-API-DMAC7.html)
ES (1) ES2785382T3 (cg-RX-API-DMAC7.html)
IL (1) IL242006B (cg-RX-API-DMAC7.html)
MX (1) MX381097B (cg-RX-API-DMAC7.html)
MY (1) MY187802A (cg-RX-API-DMAC7.html)
RU (1) RU2015143859A (cg-RX-API-DMAC7.html)
SG (2) SG10201701938PA (cg-RX-API-DMAC7.html)
WO (1) WO2014169075A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507217B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159427B1 (ko) * 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP7879845B2 (ja) * 2020-07-21 2026-06-24 アラーガン、インコーポレイテッド プロスタミドが高充填された眼内インプラント
EP4698184A1 (en) * 2023-04-18 2026-02-25 Welfare Concepts Limited Composition and method for inducing luteolysis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
ES2379652T3 (es) 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
WO2005063205A2 (en) * 2003-12-22 2005-07-14 Aventis Pharmaceuticals Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2595604B1 (en) 2010-07-21 2016-03-30 Allergan, Inc. Method of controlling initial drug release of sirna from sustained-release implants
ES2751681T3 (es) * 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
KR102159427B1 (ko) 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure

Also Published As

Publication number Publication date
MX381097B (es) 2025-03-12
MX2015014320A (es) 2015-12-08
EP3656375A1 (en) 2020-05-27
AU2019203214A1 (en) 2019-05-30
MY187802A (en) 2021-10-26
AU2014250937A1 (en) 2015-10-22
HK1221406A1 (en) 2017-06-02
KR20150141972A (ko) 2015-12-21
ES2785382T3 (es) 2020-10-06
SG10202109919PA (en) 2021-10-28
RU2015143859A (ru) 2017-05-16
CA2908731A1 (en) 2014-10-16
US10682361B2 (en) 2020-06-16
DK2983663T3 (da) 2020-04-20
CN105101962A (zh) 2015-11-25
US20140308354A1 (en) 2014-10-16
AU2019203214B2 (en) 2020-10-29
JP2016520561A (ja) 2016-07-14
WO2014169075A1 (en) 2014-10-16
RU2015143859A3 (cg-RX-API-DMAC7.html) 2018-03-05
IL242006B (en) 2020-04-30
BR112015025915A2 (pt) 2017-07-25
CL2015003023A1 (es) 2016-06-10
BR112015025915A8 (pt) 2020-01-14
EP2983663A1 (en) 2016-02-17
EP2983663B1 (en) 2020-01-22
ZA201507217B (en) 2017-09-27
NZ712804A (en) 2021-02-26
SG10201701938PA (en) 2017-04-27
US20160339039A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
Hatefi et al. Biodegradable injectable in situ forming drug delivery systems
Ruel-Gariepy et al. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs
US7767656B2 (en) Blends of temperature sensitive and anionic polymers for drug delivery
Packhaeuser et al. In situ forming parenteral drug delivery systems: an overview
EP1581181B1 (en) Controlled release depot formulations
US20040109893A1 (en) Sustained release dosage forms of anesthetics for pain management
AU2019203214B2 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
JP2005538107A5 (ja) 注入可能な多モードポリマーのデポ組成物及びその使用
EP2067468A1 (en) Sustained release dosage forms of anesthetics for pain management
JP2009509982A (ja) 内耳疾患を治療するための医薬品組成物
Vora et al. Injectable depot-forming hydrogels for long-acting drug delivery
JP2016520561A5 (cg-RX-API-DMAC7.html)
HK40025309A (en) Subtained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
US20250367110A1 (en) Compositions and methods for delivery of ocular therapeutics
HK40031326A (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
EP3986491B1 (en) Crosslinkable hydrogel compositions
HK1221406B (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
NZ712804B2 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
P Venkatesh et al. In situ gels based drug delivery systems
CN118697697B (zh) 一种脂质体封装的长效罗哌卡因缓释系统
TW202126321A (zh) 用於延長遞送以肽類為活性醫藥成分之液體聚合物組合物及系統
Patel Stimuli-Responsive Hydrogels for Parenteral Drug Delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025309

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200228

WD01 Invention patent application deemed withdrawn after publication